29,300 Shares in ICU Medical, Inc. (NASDAQ:ICUI) Bought by First Eagle Investment Management LLC

First Eagle Investment Management LLC bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 29,300 shares of the medical instruments supplier’s stock, valued at approximately $3,479,000. First Eagle Investment Management LLC owned about 0.12% of ICU Medical at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at about $32,000. Motco acquired a new position in ICU Medical during the first quarter valued at approximately $29,000. GAMMA Investing LLC grew its stake in ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 133 shares during the period. EntryPoint Capital LLC increased its position in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 2.5 %

Shares of ICUI opened at $176.74 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. ICU Medical, Inc. has a one year low of $78.28 and a one year high of $181.87. The stock has a 50-day moving average price of $149.89 and a 200 day moving average price of $121.37. The company has a market capitalization of $4.31 billion, a P/E ratio of -72.14 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. During the same quarter last year, the company earned $1.58 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Sell-side analysts forecast that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

Insider Activity

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now owns 4,482 shares in the company, valued at $645,901.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,552 shares of company stock worth $4,537,802. 6.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. KeyCorp upped their price target on shares of ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Raymond James raised their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $149.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.